Home Products Education About Us News Contact Us
VDxI Launches Blood Test for the Detection of Sepsis in Dogs
10.01.2009 | Thursday
 

                                                   

SIMI VALLEY, Calif.--(BUSINESS WIRE)—Oct 1, 2009—Veterinary Diagnostics Institute, Inc., (VDxI) a Veterinary Clinical Ventures Company dedicated to the introduction of innovative biomarkers for companion animals, announces the launch of VDxI pCNP; the first and only test to detect clinically important infections such as sepsis in canines.  The pCNP test detects N-terminal C-type natriuretic peptide (NT-proCNP) in the blood of dogs which is produced in response to an active and life threatening infection.  pCNP is patent pending.

                                                                                 

In an independent clinical study, NT-proCNP was shown to be increased by more than 5-fold in dogs with sepsis.  Additionally, the biomarker demonstrated a very high degree of specificity in differentiating dogs with sepsis from dogs with other non-infectious causes of critical illness. 

 

“Infection that causes critical illness (i.e., sepsis) is difficult to diagnose and is associated with mortality rates of 50 to 70% in dogs”, said Amy DeClue, DVM, MS, DACVIM, from the University of Missouri, College of Veterinary Medicine.  “The NT-proCNP test performed well in our study and appears to be a useful diagnostic test for sepsis in dogs.”

 

VDxI released the pCNP test and clinical study results at the 2009 International Veterinary Emergency and Critical Care Symposium (IVECCS) in Chicago.  The canine pCNP test is now available through VDxI’s reference lab services.  Studies evaluating the use of this test in felines are ongoing. 

 

“Infections are a common problem veterinarians face each day”, said Randy Ringold, President and Founder of VDxI.  “Until now there has not been a good diagnostic test.  We are very pleased in the outcome of this ground breaking research”.

 

About Veterinary Diagnostics Institute

 

VDxI, a California corporation, is a Veterinary Clinical Ventures Company, dedicated to the introduction of innovative biomarkers for companion animals.  Through collaboration with academia and in-vitro diagnostics manufacturers, VDxI addresses a growing demand in the veterinary healthcare service for advanced diagnostics.  The United States has the world’s largest population of companion animals, over 160 million, with over $20 billion spent on veterinary care each year.  For more information see www.vdxinstitute.com. 

 

Contacts:

 

General Information

Steve Gauthier

(949) 273-8378

gauthiers@vdxinstitute.com      

Why focus on new biomarker development?
What makes a diagnostic test effective?
 
Heart Disease
Heart disease is common in dogs and cats. Up to 15% of younger dogs have heart disease.1,2 The risk of heart disease increases dramatically with age; 60% of dogs may have... more
Infection
The diagnosis of clinically important infections in dogs (as in sepsis ) is a complex condition that is difficult to define, diagnose and treat. It is a range of clinical conditions... more
Cancer
Veterinary oncology, the study and treatment of cancer in companion animals, has become a growing practice in recent years. Prior to the past decade, veterinary options for therapeutic... more
Home Products Education About Us News Contact Us
© 2009 Veterinary Diagnostics Institute ™ (VDxI); All Rights Reserved